View Older Stories View More Recent Stories
-
Broadwood Partners rallies opposition to STAAR Surgical-Alcon deal
-
STAAR Surgical reports third quarter sales of $94.7 million
-
Broadwood urges STAAR board to proceed with shareholder vote on Alcon deal
-
STAAR Surgical denies receiving acquisition offers beyond Alcon bid
-
ISS joins other advisors opposing STAAR-Alcon deal
-
Broadwood Partners questions STAAR Surgical board over Alcon sale process
-
STAAR Surgical board urges shareholders to approve Alcon merger
-
Glass Lewis recommends STAAR shareholders vote against Alcon acquisition
-
Broadwood Partners challenges STAAR Surgical deal with Alcon
-
Yunqi Capital opposes STAAR Surgical merger with Alcon
-
Broadwood opposes STAAR Surgical sale at $28 after rejecting $58 offer
-
STAAR Surgical defends Alcon merger against investor objections
-
Broadwood Partners opposes STAAR Surgical sale to Alcon
-
Alcon's STAAR acquisition clears antitrust review milestone
-
SHAREHOLDER BUYOUT INVESTIGATION: Does the $28.00 Per Share Buyout Price Shortchange STAAR Surgical Company (STAA) Investors? Kaskela Law LLC is Investigating the Buyout Offer and Encourages STAA Shar
-
Broadwood opposes STAAR Surgical acquisition by Alcon
-
STAAR Surgical's merger window shop period expires without competing bids
-
Yunqi Capital opposes STAAR Surgical sale to Alcon at $28 per share
-
STAAR Surgical board recommends $28 per share Alcon merger
-
Broadwood files preliminary proxy to block STAAR Surgical sale; company responds
-
Exclusive: Shareholder revolt threatens Alcon's takeover of STAAR Surgical
-
Stifel Downgrades STAAR Surgical (STAA) to Hold
-
STAAR Surgical (STAA) Tops Q2 EPS by 22c
-
STAAR Surgical (STAA) PT Raised to $28 at Canaccord Genuity
-
Sidoti Downgrades STAAR Surgical (STAA) to Neutral
-
STAAR Surgical (STAA) Announces Appointment of Deborah Andrews as Chief Financial Officer, Forms Capital Stewardship Committee of the Board of Directors
-
Piper Sandler on STAAR Surgical (STAA): 'Challenging Macro + Management Turnover Keep Us On The Sidelines'
-
STAAR Surgical (STAA) PT Raised to $21 at Jefferies
-
STAAR Surgical (STAA) Announces $30 Million Share Repurchase Authorization
-
Stifel Reiterates Buy Rating on STAAR Surgical (STAA)
-
STAAR Surgical (STAA) PT Raised to $20 at Canaccord Genuity
-
STAAR Surgical (STAA) Misses Q1 EPS by 52c, withdraws guidance
-
STAAR Surgical (STAA) Announces Board Changes
-
Piper Sandler Reiterates Neutral Rating on STAAR Surgical (STAA) After 'A Number of Leadership Shifts'
-
BTIG Reiterates Neutral Rating on STAAR Surgical (STAA)
-
STAAR Surgical (STAA) Announces Leadership Transition
-
STAAR Surgical (STAA) PT Lowered to $17 at Canaccord Genuity
-
Jefferies Downgrades STAAR Surgical (STAA) to Hold
-
STAAR Surgical (STAA) PT Lowered to $20 at Stifel
-
STAAR Surgical (STAA) Misses Q4 EPS by 66c
-
Needham Reiterates Hold Rating on STAAR Surgical (STAA)
-
Medical Technology and Devices: Piper Sandler Shares 'Quick Thoughts on HC Conference in Jan'
-
STAAR Surgical (STAA) PT Lowered to $45 at Mizuho
-
STAAR Surgical (STAA) PT Lowered to $38 at Stifel
-
STAAR Surgical (STAA) Tops Q3 EPS by 2c, provides guidance
-
Stifel Reiterates Buy Rating on STAAR Surgical (STAA)
-
Needham Reiterates Hold Rating on STAAR Surgical (STAA)
-
STAAR Surgical (STAA) PT Lowered to $44 at Stifel
-
STAAR Surgical (STAA) Misses Q2 EPS by 9c, provides guidance
-
Morgan Stanley Downgrades STAAR Surgical (STAA) to Underweight

